DUBLIN–(BUSINESS WIRE)–The “Familial Hypercholesterolemia – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia (FH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder, which leads to a high level of LDL (bad) cholesterol. The condition begins at birth and can cause heart attacks at an early age.
FH is an autosomal-dominant disorder associated with mutations in the LDL receptor gene resulting in elevated plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). FH is significantly under-recognized with as many as 1 in 300 having the heterozygous form and one in a million having the homozygous form of the disease. Patients with FH are characterized by a decreased clearance of LDL from the circulation and an increase in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.
Heterozygous FH (HeFH) (mutation in one allele) is related with plasma LDL-C levels >190 mg/dL, whereas homozygous FH (HoFH) (mutation in both alleles) is associated with plasma LDL-C levels >500 mg/dL. As a result, there is a 20-fold increase in the risk of premature coronary heart disease (CHD) in untreated patients compared to control. HeFH patients usually develop CHD, without treatment, before age 55 and 60 for men and women, respectively. HoFH patients, however, develop CHD very early in life and can die before age 20 if untreated.
Report Highlights
Key Questions Answered
Reasons to Buy
�
Key Topics Covered:
1 Key Insights
2 Familial Hypercholesterolemia Market Overview at a Glance
2.1 Market Share (%) Distribution of Familial Hypercholesterolemia in 2017
2.2 Market Share (%) Distribution of Familial Hypercholesterolemia in 2030
3 Disease Background and Overview: Familial Hypercholesterolemia (FH)
4 Diagnostic guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)
5 Diagnostic guidelines for Familial Hypercholesterolemia by the National Institute for Health and Care Excellence (NICE)
6 Recognized Establishments
6.1 United States
6.2 Europe
6.3 Japan
7 Epidemiology and Patient Population: Key Findings
7.1 7MM Total Prevalent Population of Familial Hypercholesterolemia
7.2 7MM Total Diagnosed Prevalent Population of Familial Hypercholesterolemia
8 Country Wise-Epidemiology of Familial Hypercholesterolemia (FH)
8.1 United States
8.2 EU5 Countries
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 United Kingdom
8.7.5 Diagnosed Prevalence of Coronary Heart Disease due to Familial Hypercholesterolemia in the United Kingdom
8.8 Japan
9 Appendix
9.1 Bibliography
9.2 Report Methodology
10 Capabilities
11 Disclaimer
12 About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/xat78x.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Vietnam is increasingly popular among Indian tourists, consistently topping reports and surveys as a favoured…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 24 December 2024 - For Octa, a…
ACCRA, GHANA - Media OutReach Newswire - 24 December 2024 - 1win, in partnership with…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 24 December 2024 - Shopee Malaysia recently…
MOSCOW, RUSSIA - Media OutReach Newswire - 24 December 2024 - Wildberries, a leading e-commerce…
HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 24 December 2024 - JustMarkets…